About US
Contact us
-
Pfizer's Ibrance faces tough review at NICE, U.K. exec worriesMany drugmakers have voiced displeasure afterEngland’s cost watchdog gavenegative assessments for their promising but costly new meds. Now, though, Pfizer is voicing concerns about its Ibrance review2016/12/1
-
Bristol-Myers' Opdivo nabs European Hodgkin's nod, extending its lead in hematologyEarlier this month, Bristol-Myers Squibb’s Opdivo picked up a new indication in the U.S.—and now, it’s keeping the momentum going with another on the other side of the pond. On Wednesday, the New Jer2016/11/30
-
EpiPen maker Mylan, U.S. officials stiff-arm senator's call to testify on DOJ settlementU.S. lawmakers are still trying to hold Mylan accountable for its controversial EpiPen price hikes. But the company now flatly refuses to testify at a committee hearing convened by Sen. Charles Grassl2016/11/30
-
Pharma reps now need $750 marketing licenses to beat the streets in ChicagoIt’s official: To promote drugs in Chicago, you’ll need a $750 license—and some serious record-keeping skills. The Chicago City Council approved anordinancelast week that requires pharmaceutical sale2016/11/29
-
Pfizer sues Texas agency for leaking 'confidential' Medicaid pricing dealsPfizer has faced scrutiny for its drug pricing over the last year, but now it’s bringing some heat of its own to protect those numbers from prying eyes. The pharma giant last week sueda Texasagency, c2016/11/29
-
Neovacs and 3P Biopharmaceuticals partner to manufacture IFNaFrench company Neovacs and Spanish-based 3P Biopharmaceuticals have collaborated to manufacture interferon alpha (IFNα). The partnership follows the recent acquisition of the technology for the manuf2016/11/28
-
M&As this week: Sun Pharmaceuticals, AllerganSun Pharmaceuticals Industriesplans to acquire an 85.1% stake in JSC Biosintez for a purchase consideration of $60m. The acquisition will enable Sun Pharmaceuticals to gain local manufacturing capa2016/11/28
-
Pharma already balks at Germany's tough pricing regime--and it could get even tougherGermany may stiffen up its already strict drug pricing rules, a move that could exacerbate the pharma industry’s sometimes-acrimonious relationship with health officials there. Under a proposal now u2016/11/25
-
Brexit battle heats up over winning EMA from LondonA long list of EU countries would love to behometo the European Medicines Agency (EMA) post-Brexit--France, Italy, Denmark, Sweden, Hungary and more. But the U.K. is not going to let it go without put2016/11/25
-
FDA nod helps BMS' Opdivo even the head-and-neck cancer score with Merck's KeytrudaThursday was quite the day for Bristol-Myers Squibb’s Opdivo. After becoming the first med to succeed in a Phase III gastric cancer trial, the drug nabbed anFDA approvalin head-and-neck cancer--and ev2016/11/24